AG
TGTX icon

Aperio Group’s TG Therapeutics TGTX Stock Holding History

Aperio Group’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$716K Buy
13,767
+2,476
+22% +$83.7K ﹤0.01% 1773
2020
Q3 		$302K Buy
+11,291
New +$260K ﹤0.01% 2066
2019
Q3 		– Sell
-3,727
Closed -$32K – 2718
2019
Q2 		$32K Buy
+3,727
New +$28.2K ﹤0.01% 2617

Other funds holding TGTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Aperio Group's TGTX Position: Q4 2020 in Review

Aperio Group increased its TG Therapeutics (TGTX) stake by 22% in Q4 2020, buying an estimated $83.7K and bringing the position to 13,767 shares worth $716K. The position accounts for ﹤0.01% of the portfolio, ranked #1773.

Aperio Group first reported a position in TGTX in Q2 2019 and has held it in 3 quarters since. 247 funds tracked by Wall St. Rank hold TGTX as of Q4 2020.

  • Aperio Group held 13,767 shares of TG Therapeutics worth $716K as of Q4 2020.
  • Aperio Group bought 2,476 TG Therapeutics shares in Q4 2020, an estimated $83.7K.
  • TG Therapeutics made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #1773 holding.
  • Aperio Group first reported a position in TG Therapeutics in Q2 2019 and has held it in 3 quarters since.
  • 247 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.